Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Mar 26, 2019 4:35 PM EDT
Oligonucleotide & Precision Therapeutics (OPT) Congress
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “siRNA Clinical Development Based on the TRiMTM Platform”
Cambridge, MA
Mar 27 - Mar 30, 2019
CSHL Meeting: RNA & Oligonucleotide Therapeutics
Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular and lipid disorders - A next frontier for TRiMTM RNAi”
Cold Spring Harbor, NY
Apr 3, 2019 8:00 AM EDT
AACR Annual Meeting 2019
So Wong, Ph.D., Arrowhead’s director of oncology, will deliver a poster presentation titled, “Optimizing the potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear cell renal cell carcinoma”
Apr 10, 2019
The EASL International Liver Congress 2019

Oral Presentation:
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold

  • Presentation Reference: PS-080
  • Session: Parallel session: Hepatitis B - drug development
  • Date and Time: April 12, 2019 at 5:45 p.m. CET
  • Authors: Man-Fung Yuen, et al.

Poster Presentation:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model

  • Presentation Reference: FRI-446
  • Session: Poster: Rare liver diseases (including pediatric and genetic)
  • Session Date and Time: April 12, 2019 from 9 a.m. to 5 p.m. CET
  • Authors: Christine Wooddell, et al.
Archived Events
Date Event Details
Sep 25, 2017 9:10 AM EDT
2017 Cantor Fitzgerald Global Healthcare Conference
Sep 14, 2017 1:00 PM EDT
Arrowhead Analyst R&D Day
Aug 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Third Quarter Results
May 5, 2017 11:30 AM CDT
Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017 Scientific Sessions

Location: Minneapolis, MN

Title: Factor 12 RNAi-based therapeutic as a prophylactic anti-thrombotic therapy

May 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Second Quarter Results
Apr 19 - Apr 23, 2017 12:00 AM EDT
The EASL International Liver Congress™ 2017
Amsterdam, The Netherlands

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

  • Presentation Reference: PS-045
  • Session: Parallel session: Hepatitis B and D: Emerging treatment options
  • Date and Time: April 20, 2017 at 5:30 PM CET
  • Authors: Man-Fung Yuen, et al.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

  • Presentation Reference: THU-176
  • Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
  • Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
  • Authors: Edward Gane, et al.

Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients

  • Presentation Reference: LBO-06
  • Session: Late Breaker session
  • Date and Time: April 22, 2017 at 5:15 PM CET
  • Authors: Alice Turner, et al.
Feb 21 - Feb 23, 2017 12:00 AM EST
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Kyoto, Japan
Feb 6, 2017 4:30 PM EST
Arrowhead Fiscal 2017 First Quarter Results
Dec 14, 2016 4:30 PM EST
Arrowhead Fiscal 2016 Year End Results
Nov 30, 2016 8:30 AM EST
The 28th Annual Piper Jaffray Healthcare Conference
New York

November 30, 8:30 a.m. EST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray.

Presentation Canceled